Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'Fund it properly or it will implode': parting comments from Aginus Kalis on EU drug regulatory network

This article was originally published in SRA

Executive Summary

“If you don’t finance it correctly, it will implode.” This was the stark warning key European drug regulator Aginus Kalis gave about the European drug regulatory network in an exclusive interview to Scrip Regulatory Affairs on his last day as executive director of the Dutch Medicines Evaluation Board.

You may also be interested in...

Submit Your Brexit-Related Changes Before We Move: EMA Plea To Industry

A continuous two-way dialogue on Brexit between the European Medicines Agency and industry is a must. The EMA is tentatively planning three Brexit-related events for stakeholders and, in the meantime, it wants companies to keep it abreast of their plans for products affected by the UK’s departure from the EU

Sanofi Seeks Double Vaccine Approval Nod In EU

The sponsors of up to seven new drugs or vaccines will find out this week whether their products will soon be approved in the EU. The products include two vaccines from Sanofi and what is possibly the first generic rival to Bayer's Xarelto to be assessed by the European Medicines Agency.

EU Fast-Track Review In Store For Takeda’s Dengue Vaccine

Takeda will soon seek EU approval of its dengue vaccine candidate. The marketing application will be fast-tracked, as will the applications for Regeneron's evinacumab and bluebird bio's eli-cel Lenti-D gene therapy.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts